Regeneron and Gilead Stock Jump as President Trump’s Health Remains in Focus

(MarketWatch) – Donald Trump’s health remains the focus on Monday morning after the president revealed his positive Covid-19 test on Friday.

The president’s doctors gave him experimental antibody medication from Regeneron Pharmaceuticals, as well as Gilead Sciences ’ antiviral drug Remdesivir, to help speed recovery.

Both of those stocks are reacting. Regeneron stock is up about 5% in premarket trading, while Gilead is up about 3%.

Shares of other pharmaceutical companies making treatments and vaccines are getting a bump as well. Moderna, which has a vaccine in trials, is up 2%, while BioNTech and Inovio Pharmaceuticals, which also have vaccine programs under way, are up 3% and 2%, respectively.

Some pharmaceutical giants with vaccine programs are higher as well, though not nearly as much. GlaxoSmithKline and Johnson & Johnson are up about 1% in premarket trading.

That’s been the story of the year. Shares of Regeneron, BioNTech, Moderna, and Inovio have been big winners. That quartet is up an average of 168% in 2020. Large, diversified pharma companies, including Johnson & Johnson and Glaxo, are still down this year.

Share: